Researchers have identified specific brain wave patterns in the basal ganglia that correlate with Parkinson's symptoms, potentially enabling more precise and dynamic deep brain stimulation therapies to improve motor control.
Researchers conducted experiments on mice to investigate minute-scale oscillatory sequences in the medial entorhinal cortex (MEC). They performed surgeries to implant microprisms or glass windows for optical access to the MEC and adjacent areas. Two-photon calcium imaging and electrophysiological data were collected, and Neuropixels probes were used for recording neural signals. The mice were trained to run on a wheel under minimal sensory stimulation conditions. The study provides insights into the neural activity patterns in the MEC and their potential role in spatial navigation and memory.
Medtronic has received FDA approval for its PulseSelect Pulsed Field Ablation (PFA) System, making it the first PFA technology to be approved. The system provides a safe and effective treatment for both paroxysmal and persistent atrial fibrillation (AF). It offers differentiated safety features, rapid pulmonary vein isolation, and a seamless transition to PFA in a clinician's workflow. The approval follows the recent European CE Mark of the PulseSelect PFA system. Commercialization is set to begin in early 2024.